High Demand Slows Launch of Novo Nordisk’s Obesity Drug Wegovy in New Markets

Tue Jun 20 2023
icon-facebook icon-twitter icon-whatsapp

LONDON: Novo Nordisk, a global healthcare company specializing in diabetes care, is adjusting the launch strategy for its obesity drug Wegovy in new markets due to unexpectedly high demand in the three countries where it is currently available, according to an executive statement on Tuesday.

Camilla Sylvest, the Executive Vice President of Commercial Strategy and Corporate Affairs at Novo Nordisk, made the announcement during a press conference.

Wegovy, a weekly injection, was initially launched in the United States in June 2021 and has since garnered significant attention from patients, investors, and celebrities alike. When combined with dietary and exercise changes, the drug has demonstrated an average weight loss of approximately 15 percent, making it a promising solution for individuals struggling with obesity.

Novo Nordisk Cautious to Drug’s Introduction in New Markets

Due to the overwhelming response and demand experienced in the initial markets, Novo Nordisk has decided to take a more cautious approach to the drug’s introduction in new markets. Camilla Sylvest acknowledged that the launch in these regions would be conducted “a little slower than planned” to ensure a smooth and efficient supply chain while meeting the increasing demand.

The precise details regarding the specific new markets and the revised launch timeline were not disclosed during the press conference. However, it is evident that Novo Nordisk intends to manage the situation carefully to avoid any potential supply shortages or disruptions.

The global obesity epidemic has prompted significant interest in Wegovy, as it offers a promising treatment option for individuals seeking to manage their weight effectively. Novo Nordisk’s decision to adapt its launch strategy reflects the drug’s significant impact and the growing demand for a solution to combat obesity.

icon-facebook icon-twitter icon-whatsapp